Infertility Drugs Market Size, Share, and Trends 2024 to 2033

Infertility Drugs Market (By Drug Class: Gonadotropins, Aromatase Inhibitors, Selective Estrogen Receptor Modulators (SERMs), Dopamine Agonists, Others; By Distribution Channel: Hospital Pharmacy, Specialty & Retail Pharmacy, Online Pharmacy; By End-user: Men, Women) - Global Industry Analysis, Size, Share, Growth, Trends, Regional Outlook, and Forecast 2024-2033

  • Last Updated : May 2024
  • Report Code : 4243
  • Category : Healthcare

Infertility Drugs Market Size and Growth 2024 to 2033

The global infertility drugs market size was valued at USD 3.71 billion in 2023 and is predicted to reach around USD 6.73 billion by 2033, growing at a CAGR of 6.13% from 2024 to 2033. The primary reasons behind the growth of this market are developments in healthcare facilities and a desire for parenthood among married couples.

Infertility Drugs Market Size 2024 to 2033

Infertility Drugs Market Key Takeaways

  • The global infertility drugs market size accounted for USD 1.45 billion in 2023 and is expected to rise around USD 2.65 billion by 2033.
  • North America dominated the market with the largest market share of 39% in 2023.
  • Asia Pacific is expected to expand at the fastest CAGR of 6.93% during the forecast period.
  • By drug class, the gonadotropins segment has contributed more than 41% of market share in 2023.
  • By the drug class, the selective estrogen receptor modulators segment is predicted to show rapid growth in the market.
  • By the distribution channel, the hospital pharmacy segment has generated more than 55% of market share in 2023.
  • By distribution channel, the online pharmacy segment is expected to grow at a high rate over the forecast period.
  • By end-user, the women segment has contributed more than 74% of market share in 2023.
  • By end-user, the men segment will be the fastest-growing segment during the forecast period.

Infertility Drugs Market Size in the U.S. 2024 to 2033

The U.S. infertility drugs market size reached USD 1.16 billion in 2023 and is predicted to be worth around USD 2.11 billion by 2033, at a CAGR of 6.16% from 2024 to 2033.

U.S. Infertility Drugs Market Size 2024 to 2033

North America dominated the infertility drugs market in 2023. The biggest reason why we see a large sale of infertility drugs in North America is that the lifestyle followed by North American people is extremely unhealthy. Due to a high amount of sugary and salty foods, there is a rise in obesity and eating disorders, which hampers sperm quality or leads to poor reproductive health in females. Another main issue is the habit of smoking. Recent reports say that one in five deaths in the U.S. happens because of smoking. Smoking can hamper sperm quality, making them weak and reducing their mobility.

  • According to the Journal of Nutrition published in 2022, adults in the U.S. consume about 4.8 junk food items daily.

Asia Pacific will have the fastest growth rate in the global infertility drugs market during the forecast period. Infertility is rising in Asia Pacific because of several factors. People are choosing to marry late while focusing on their careers in countries like India. A trend has been seen that people with higher education levels and late marriages show primary infertility. Apart from this, smoking, tobacco consumption, obesity, and other diseases show their link with secondary infertility. Several awareness programs have been conducted, and people have become alert about their reproductive health because of this.

Infertility Drugs Market Size in the Asia Pacific 2024 to 2033

The Asia Pacific infertility drugs market size was calculated at USD 1.04 billion in 2023 and is estimated to cross around USD 1.92 billion by 2033 with a notable CAGR of 6.32% from 2024 to 2033.

Year Market Size (USD Billion)
2023 1.04
2024 1.10
2025 1.17
2026 1.24
2027 1.32
2028 1.40
2029 1.48
2030 1.58
2031 1.67
2032 1.78
2033 1.92

Infertility Drugs Market Overview

Infertility is a condition of not being able to achieve pregnancy after 12 months or more of regular unprotected sex. Infertility is divided into primary and secondary infertility. Primary infertility is when parents are unable to conceive for the first child, and secondary infertility is when parents are unable to conceive for the second child. Infertility issues can be in men and women as well. Sometimes, there can be an issue with both partners and sometimes, it can be totally unexplained. There are many reasons behind infertility, and it mainly depends upon the lifestyle of both partners. If the partners have addictions like smoking, drinking, or obesity due to bad food habits, this can affect reproductive fitness adversely and can lead to impotence in males and the inability to conceive in females.

Infertility Drugs Market Growth Factors

  • Bad lifestyle, including habits like smoking, drinking, unhealthy sleep schedules, excess junk food consumption, etc.
  • Sedentary work and lack of exercise
  • People marrying late in their life
  • Marijuana use
  • Being overweight or being underweight.

Infertility Drugs Market Scope

Report Coverage Details
Growth Rate from 2024 to 2033 CAGR of 6.13%
Global Market Size in 2023 USD 3.71 Billion
Global Market Size in 2024 USD 3.94 Billion
Global Market Size by 2033 USD 6.73 Billion
Largest Market North America
Base Year 2023
Forecast Period 2024 to 2033
Segments Covered By Drug Class, By Distribution Channel, and By End-user
Regions Covered North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa


Infertility Drugs Market Dynamics

Drivers: Bad lifestyle

Due to bad habits and addictions, an increasing population is getting infertile. Smoking has become a new trend. Many corporate employees and students catch a habit of smoking in their life at some stage and become addicted to it. However, smoking and alcoholism can have severe effects on the reproductive system of males as well as females. In males, such bad habits can lead to impotence or erectile dysfunction, and in females, it can lead to an inability to conceive. Awareness is being spread regarding infertility issues through advertisements and even movies that talk about infertility.

Restraint: Awareness issues and side effects

Infertility is a subject that is thought to be taboo and shameful in many villages. It is thought to be shameful not being able to conceive. In many Indian villages, due to a lack of education, women are thought to be solely responsible for not being able to conceive. There is an importance of awareness in these areas. Infertility drugs of high quality should be made aware in government hospitals, and awareness should be spread, too. Infertility drugs, however, are expensive and are not affordable for many people. There is also a stigma in society when someone consumes such drugs, and people are hesitant when it comes to getting treatment for infertility. Infertility drugs need proper testing and approval processes, which can take a long time. Also, testing them on subjects can cause problems with their health. Infertility drugs can have potential side effects, too; for example, the child might have poor immunity and health issues in the future.

Opportunities: Another reproductive health market

The infertility drugs market will open opportunities for several other markets like childcare, IVF, etc. There will be a growth in healthcare infrastructure, and more awareness about infertility will spread. Due to more advancements in technology, people can produce healthy babies. The infertility drugs market will also boost the surrogacy market and infertility tourism. Parents can travel to different countries to get effective treatments for infertility. More awareness about infertility in rural areas as well as urban areas will help fight the stigma that people have regarding infertility.        

Drug Class Insights 

According to the drug class, the gonadotropins segment dominated the infertility drugs market in 2023 and is expected to continue this dominance throughout the forecast period. It will achieve the highest growth during the forecast period. Gonadotropins are high in cost and are used widely. Gonadotropins are naturally produced by the pituitary glands and stimulate the ovaries to produce a ‘follicle’ containing an egg, which then releases the egg from the ovary. For those who are not able to ovulate, gonadotropins are given to stimulate ovulation. Gonadotropin helps those who are ovulating but are facing problems in conceiving. Gonadotropins for medical purposes are produced in the laboratory and injected under the skin to be effective. It is generally given to women who do not have regular menstrual periods and have very low levels of LH and FSH hormones.

According to the drug class, the selective estrogen receptor modulators segment is predicted to show rapid growth in the infertility drugs market. SERMs are used for indcing ovulation in women having ovulation disorders. SERMs can stimulate ovulation and hence improve the chances of getting pregnant. Some SERMs also find uses in breast cancer treatment, and this, too, helps grow the market. For example, tamoxifen is a drug that can induce ovulation and can also stop the activity of estrogen in the breasts.

Distribution Channel Insights

According to the distribution channel, the hospital pharmacy segment dominated the infertility drugs market in 2023. This is because people prefer to have a proper consultation and treatment with highly qualified professional doctors and then take the medicines. This channel is more popular because patients can get physically diagnosed by the doctors and continue the consultation, visit clinics for regular checkups, and there is a sense of assurance and security in a couple’s mind.

In the infertility drugs market, the online pharmacy segment is expected to grow at a high rate over the forecast period. Ordering online is accessible and convenient. Online medicine delivery has become convenient, and people who don’t have access to shops nearby or live in remote areas can consult doctors online and order medicines. Privacy is assured when ordering online, as many people find it to be embarrassing due to social pressures and stigma. There is also a wider variety of medications available online. Online websites also provide discounts. People can get effective customer support when ordering online.

End-user Insights

By end-user, the women segment dominated the infertility drugs market in 2023. It has been found that women show higher depression levels than men when it comes to infertility. This is mainly because of the social stigma and a lack of knowledge in the orthodox families. Studies have also shown that a failure in one treatment shows a higher level of distress in women when taking treatment next time. In some societies, women are considered to be solely responsible for the infertility issues. Infertility issues in women can be complex. There can be issues with ovulation, blockages in the fallopian tubes, or other abnormalities in the uterus. Women are also more aware of their reproductive health.

Infertility Drugs Market Share, By Region, 2023 (%)

In the infertility drugs market, the men segment will be the fastest-growing segment during the forecast period. There is a growing awareness of male infertility. Many males are working professionals and catch bad habits and addictions like smoking or drinking. This often leads to a low sperm count, a fall in sperm motility, sperm deformation, or impotence. Men also take infertility treatment to accompany their spouses, as couples have become aware that the problem might lie with either of them. Regular checkups are done in order to check if there are any other health issues like genetic factors or hormonal issues.

Infertility Drugs Market Recent Developments

  • In February 2024, Lupin, a major global pharma company, launched Ganirelix Acetate Injection. It is a single-dose prefilled syringe indicated for inhibiting premature luteinizing hormone (LH) surges in women who undergo ovarian hyperstimulation.
  • In March 2024, Future Generali India Insurance launched ‘Health PowHER’, a product designed exclusively for women healthcare at various stages of their lives. There will be varios treatments offered by the product, and one of the treatments will be infertility treatment. This will include oocyte cryopreservation, stem cell storage, wellness programme, insurance for newborn defects, nursing care, and many more benefits.

Infertility Drugs Market Companies

  • Merck & Co., Inc.
  • Ferring B.V.
  • Organon Group of Companies
  • Abbott
  • Novartis AG
  • Bayer AG
  • Pfizer Inc.
  • Mankind Pharma
  • Teva Pharmaceutical Industries LTD.
  • Sanofi 

Segments Covered in the Report

By Drug Class

  • Gonadotropins
  • Aromatase Inhibitors
  • Selective Estrogen Receptor Modulators (SERMs)
  • Dopamine Agonists
  • Others

By Distribution Channel

  • Hospital Pharmacy
  • Specialty & Retail Pharmacy
  • Online Pharmacy

By End-user

  • Men
  • Women

By Geography

  • North America
  • Asia Pacific
  • Europe
  • Latin America
  • Middle East & Africa

Frequently Asked Questions

The global infertility drugs market size is expected to increase USD 6.73 billion by 2033 from USD 3.71 billion in 2023.

The global infertility drugs market will register growth rate of 6.13% between 2024 and 2033.

The major players operating in the infertility drugs market are Merck & Co., Inc., Ferring B.V., Organon Group of Companies, Abbott, Novartis AG, Bayer AG, Pfizer Inc., Mankind Pharma, Teva Pharmaceutical Industries LTD., Sanofi and Others.

The driving factors of the infertility drugs market are the bad lifestyle and rising awareness and acceptance of infertility treatments.

North America region will lead the global infertility drugs market during the forecast period 2024 to 2033.

Ask For Sample

No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client

Related Reports